GE HealthCare Technologies Inc. Stock Börse Stuttgart

Equities

L0T

US36266G1076

Advanced Medical Equipment & Technology

Market Closed - Börse Stuttgart 02:06:56 2024-07-03 am EDT After market 03:59:06 pm
70.68 EUR +0.06% Intraday chart for GE HealthCare Technologies Inc. 71.58 +1.28%
Sales 2024 * 20.14B 18.67B Sales 2025 * 21.13B 19.59B Capitalization 35.26B 32.69B
Net income 2024 * 1.86B 1.72B Net income 2025 * 2.12B 1.96B EV / Sales 2024 * 2.01 x
Net Debt 2024 * 5.23B 4.85B Net Debt 2025 * 3.2B 2.97B EV / Sales 2025 * 1.82 x
P/E ratio 2024 *
18.8 x
P/E ratio 2025 *
16.6 x
Employees 51,000
Yield 2024 *
0.12%
Yield 2025 *
0.19%
Free-Float 93.07%
More Fundamentals * Assessed data
Dynamic Chart
UBS Adjusts Price Target on GE HealthCare Technologies to $84 From $88, Maintains Neutral Rating MT
GE HealthCare Technologies Inc.(NasdaqGS:GEHC) added to Russell Midcap Value Index CI
GE HealthCare Technologies Keeps Quarterly Dividend at $0.03 Per Share, Payable Aug. 15 to Shareholders of Record on July 19 MT
GE HealthCare Technologies Inc. Announces Cash Dividend for Second Quarter of 2024, Payable on August 15, 2024 CI
GE HealthCare Partners With New Mexico Hospital to Install Allia IGS Pulse Electrophysiology Lab MT
GE HealthCare, MediView Report Clinical Use of OmnifyXR Interventional Suite MT
GE Healthcare and Mediview Announce the World's First Installation and Clinical Use of Augmented Reality Interventional Suite That Aims to Transform the Practice of Interventional Radiology CI
GE HealthCare Reports Changes in Key Segments MT
GE Healthcare Technologies Inc. Announces Management Changes CI
Transcript : GE HealthCare Technologies Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 10:00 AM
Nucleus RadioPharma, Inc. announced that it has received $66.099956 million in funding from a group of investors CI
GE HealthCare, Tampa General Hospital Expand Collaboration in Imaging, Ultrasound Technology MT
GE Healthcare and Tampa General Hospital Expand Long-Term Partnership to Benefit Patients and Clinicians Across the State of Florida CI
Goldman Sachs Initiates GE HealthCare Technologies With Neutral Rating, $87 Price Target MT
GE Healthcare Names Adam Holton as Chief People Officer CI
More news
1 day+1.34%
1 week-3.59%
Current month-3.90%
1 month-1.94%
3 months-14.33%
6 months+2.43%
Current year+0.97%
More quotes
1 week
70.68
Extreme 70.68
73.55
1 month
69.75
Extreme 69.75
74.02
Current year
65.00
Extreme 65
86.50
1 year
58.50
Extreme 58.5
86.50
3 years
51.81
Extreme 51.81
86.50
5 years
51.81
Extreme 51.81
86.50
10 years
51.81
Extreme 51.81
86.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 22-12-13
Director of Finance/CFO 51 23-05-31
Chief Tech/Sci/R&D Officer - 22-09-30
Members of the board TitleAgeSince
Director/Board Member 65 22-12-13
Chief Executive Officer 59 22-12-13
Chairman 60 23-01-02
More insiders
Date Price Change Volume
24-07-03 70.68 +0.06% 0
24-07-01 70.84 -3.68% 8
24-06-28 73.55 +0.33% 333
24-06-26 73.31 +0.29% 180

Delayed Quote Börse Stuttgart, July 03, 2024 at 02:06 am EDT

More quotes
GE HealthCare Technologies Inc. is a medical technology, pharmaceutical diagnostics, and digital solutions company. It develops, manufactures, and markets a portfolio of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients. Its segments include Imaging, Ultrasound, Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its Imaging segment offers a comprehensive portfolio of scanning devices, clinical applications, service capabilities, and digital solutions. Its Ultrasound segment includes ultrasound medical devices and solutions with a portfolio of continuum of care, including screening, diagnosis, treatment, and monitoring of certain diseases. Its PCS segment portfolio is comprised of patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, maternal infant care, and consumables and services. Its PDx segment is comprised of two business lines: contrast media and molecular imaging.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
76.33 USD
Average target price
92.45 USD
Spread / Average Target
+21.12%
Consensus